Brown Advisory Inc. Reduces Position in Stryker Co. (NYSE:SYK)

Brown Advisory Inc. trimmed its position in Stryker Co. (NYSE:SYK - Free Report) by 21.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,086 shares of the medical technology company's stock after selling 12,778 shares during the quarter. Brown Advisory Inc.'s holdings in Stryker were worth $16,593,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Stryker in the fourth quarter worth $1,710,744,000. Raymond James Financial Inc. purchased a new stake in shares of Stryker in the 4th quarter worth about $353,394,000. FMR LLC boosted its stake in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after purchasing an additional 727,850 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Stryker by 52,520.8% during the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock valued at $214,660,000 after purchasing an additional 595,061 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after buying an additional 420,153 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of NYSE SYK opened at $377.77 on Wednesday. The stock has a market cap of $144.19 billion, a PE ratio of 48.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a fifty day moving average price of $365.95 and a 200-day moving average price of $374.03. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.50 earnings per share. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SYK. Evercore ISI reduced their price target on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Wells Fargo & Company boosted their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Roth Mkm increased their target price on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Barclays lifted their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Finally, Royal Bank of Canada increased their price target on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $425.84.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.